185 related articles for article (PubMed ID: 19896080)
21. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A; Kröger N; Zabelina T; Ayuk F; Hardan I; Yeshurun M; Shem-Tov N; Avigdor A; Ben-Bassat I; Zander AR; Nagler A
Leukemia; 2005 Jan; 19(1):7-12. PubMed ID: 15526016
[TBL] [Abstract][Full Text] [Related]
23. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
26. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
[TBL] [Abstract][Full Text] [Related]
27. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
[TBL] [Abstract][Full Text] [Related]
29. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY
Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002
[TBL] [Abstract][Full Text] [Related]
31. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
32. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
33. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
34. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
35. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
[TBL] [Abstract][Full Text] [Related]
36. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
[TBL] [Abstract][Full Text] [Related]
38. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
[TBL] [Abstract][Full Text] [Related]
40. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
